secwatch / observer
8-K filed March 18, 2025, 7:59 PM ET ticker WHWK CIK 0001422142
other material confidence high sentiment positive materiality 0.80

Aadi Bioscience relaunches as Whitehawk Therapeutics; reports FY2024 net loss $63.7M, $100M PIPE closed

Whitehawk Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.99

Whitehawk Therapeutics, Inc.: Company amended its certificate of incorporation to change its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc (effective 2025-03-18).

Change
charter amendment
Effective
2025-03-18
Exact text from the filing
The board of directors (the “ Board ”) of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “ Charter ”), to change the Company’s name to Whitehawk Therapeutics, Inc. (the “ Name Change ”). On March 18, 2025, the Company filed a certificate of amendment (the “ Name Change Charter Amendment ”) to the Charter with the Secretary of State of the State of Delaware, which effected the Name Change.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.99

Whitehawk Therapeutics, Inc.: Board approved an amendment and restatement of the bylaws solely to reflect the name change to Whitehawk Therapeutics, Inc (effective 2025-03-18).

Change
bylaw amendment
Effective
2025-03-18
Exact text from the filing
Additionally, the Board approved an amendment and restatement of the Company’s bylaws solely to reflect the Name Change (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws became effective upon the effectiveness of the Name Change Charter Amendment.
View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-25-056708
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.